Wednesday, February 18, 2026 2/18/2026

Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.

Award Number: R21CA256280
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/09/2020
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging. - Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging Project Summary / Abstract Invasive lobular breast cancer (ILC) accounts for approximately 10-15% of breast malignancies and has an underlying metastatic rate of up to 43%. ILC has discohesive growth making metastasis difficult to visualize with conventional imaging modalities such as computed tomography (CT), bone scan, and magnetic resonance imaging (MR). Suboptimal imaging adversely impacts accurate staging upon which therapeutic decisions are based. While fluorodeoxyglucose (FDG) PET has been shown to clinically upstage patients with locally advanced IDC, this is not so with ILC, which has been described as “initially indolent but slowly progressive”. There are no accurate imaging techniques for staging ILC. Our goal is to address an unmet public health need by improved staging of ILC, specifically detection of metastatic disease. Amino acid transporters are upregulated in breast cancer cells. We and others have successfully imaged breast cancer with fluciclovine (18F) PET, an FDA approved synthetic amino acid radiotracer originally developed at Emory for imaging of cerebral glioma and prostate cancer. In exploratory studies conducted at Emory and Memorial Sloan Kettering in 39 women with breast cancer (13 patients with ILC), fluciclovine PET demonstrated promising results in detection of ILC in primary tumors and locoregional metastases. Distant disease was not studied. There is emerging data that imaging with prostate specific membrane antigen (PSMA) PET may improve detection of breast cancer, including ILC. Prostate-specific is actually a misnomer as PSMA receptors are upregulated in tumor neovasculature in many cancers including breast cancer. PSMA targeting of lobular breast cancer for more effective staging has been strongly encouraged by experts in the field. We hypothesize that metabolic imaging with amino acid transporter PET will improve staging of ILC, particularly for distant metastases, compared to conventional imaging. We also hypothesize that receptor directed PSMA imaging of tumor associated neovasculature in ILC will reveal unique information to complement metabolic interrogation with fluciclovine PET. To test these hypotheses with the highest scientific rigor, we propose an early phase trial with fluciclovine and PSMA PET strategies centered on detection of metastasis in patients with advanced ILC using histology as the gold standard. As an exploratory aim, we will also correlate the occurrence of circulating tumor DNA (ctDNA) mutations including PIK3CA, ESR1, HER2, and AKT1 with presence of metastasis and tumor burden. We expect this study will generate sufficient preliminary data to determine feasibility for a definitive NIH sponsored multi-center trial developing more accurate staging techniques to alter current practice for imaging of ILC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	EMORY UNIVERSITY	201 DOWMAN DR NE	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	2	3/28/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	2	2/23/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $193,293 )
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	001	2	4/26/2022	NON-COMPETING CONTINUATION	$15,779
2022	2022	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	2	11/4/2021	NON-COMPETING CONTINUATION	$177,514
														Subtotal = $193,293

Issue Date FY: 2021 ( Subtotal = $169,125 )
2021	2021	EMORY UNIVERSITY	201 DOWMAN DR	ATLANTA	GA	30322	DEKALB	USA	Cancer Detection and Diagnosis Research	000	1	12/9/2020	NEW	$169,125
														Subtotal = $169,125

Grand Total All Awards = $362,418

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.

Award Number: R21CA256280

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/09/2020

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer